136 related articles for article (PubMed ID: 11597826)
1. Urocortin protects against ischemic injury via a MAPK-dependent pathway.
Latchman DS
Trends Cardiovasc Med; 2001 Jul; 11(5):167-9. PubMed ID: 11597826
[TBL] [Abstract][Full Text] [Related]
2. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway.
Brar BK; Jonassen AK; Stephanou A; Santilli G; Railson J; Knight RA; Yellon DM; Latchman DS
J Biol Chem; 2000 Mar; 275(12):8508-14. PubMed ID: 10722688
[TBL] [Abstract][Full Text] [Related]
3. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart.
Brar BK; Jonassen AK; Egorina EM; Chen A; Negro A; Perrin MH; Mjøs OD; Latchman DS; Lee KF; Vale W
Endocrinology; 2004 Jan; 145(1):24-35; discussion 21-3. PubMed ID: 12970163
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes.
Chanalaris A; Lawrence KM; Stephanou A; Knight RD; Hsu SY; Hsueh AJ; Latchman DS
J Mol Cell Cardiol; 2003 Oct; 35(10):1295-305. PubMed ID: 14519439
[TBL] [Abstract][Full Text] [Related]
5. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death.
Brar BK; Stephanou A; Knight R; Latchman DS
J Mol Cell Cardiol; 2002 Apr; 34(4):483-92. PubMed ID: 11991736
[TBL] [Abstract][Full Text] [Related]
6. Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway.
Schulman D; Latchman DS; Yellon DM
Am J Physiol Heart Circ Physiol; 2002 Oct; 283(4):H1481-8. PubMed ID: 12234800
[TBL] [Abstract][Full Text] [Related]
7. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides.
Brar BK; Chen A; Perrin MH; Vale W
Endocrinology; 2004 Apr; 145(4):1718-29. PubMed ID: 14670995
[TBL] [Abstract][Full Text] [Related]
8. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart.
Kimura Y; Takahashi K; Totsune K; Muramatsu Y; Kaneko C; Darnel AD; Suzuki T; Ebina M; Nukiwa T; Sasano H
J Clin Endocrinol Metab; 2002 Jan; 87(1):340-6. PubMed ID: 11788672
[TBL] [Abstract][Full Text] [Related]
9. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart.
Li J; Qi D; Cheng H; Hu X; Miller EJ; Wu X; Russell KS; Mikush N; Zhang J; Xiao L; Sherwin RS; Young LH
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16133-8. PubMed ID: 24043794
[TBL] [Abstract][Full Text] [Related]
10. Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes.
Railson JE; Liao Z; Brar BK; Buddle JC; Pennica D; Stephanou A; Latchman DS
Cytokine; 2002 Mar; 17(5):243-53. PubMed ID: 12027405
[TBL] [Abstract][Full Text] [Related]
11. Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins.
Grammatopoulos DK; Randeva HS; Levine MA; Katsanou ES; Hillhouse EW
Mol Endocrinol; 2000 Dec; 14(12):2076-91. PubMed ID: 11117536
[TBL] [Abstract][Full Text] [Related]
12. Activation of corticotropin releasing factor receptor type 2 in the heart by corticotropin releasing factor offers cytoprotection against ischemic injury via PKA and PKC dependent signaling.
Jonassen AK; Wergeland A; Helgeland E; Mjøs OD; Brar BK
Regul Pept; 2012 Feb; 174(1-3):90-7. PubMed ID: 22209828
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective action of urocortin in early pre- and postconditioning.
Cserepes B; Jancsó G; Gasz B; Rácz B; Ferenc A; Benkó L; Borsiczky B; Kürthy M; Ferencz S; Lantos J; Gál J; Arató E; Miseta A; Wéber G; Róth E
Ann N Y Acad Sci; 2007 Jan; 1095():228-39. PubMed ID: 17404036
[TBL] [Abstract][Full Text] [Related]
14. The neurobiology of urocortin.
Skelton KH; Owens MJ; Nemeroff CB
Regul Pept; 2000 Sep; 93(1-3):85-92. PubMed ID: 11033056
[TBL] [Abstract][Full Text] [Related]
15. Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval.
Fekete EM; Inoue K; Zhao Y; Rivier JE; Vale WW; Szücs A; Koob GF; Zorrilla EP
Neuropsychopharmacology; 2007 May; 32(5):1052-68. PubMed ID: 17019404
[TBL] [Abstract][Full Text] [Related]
16. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors.
Bittencourt JC; Vaughan J; Arias C; Rissman RA; Vale WW; Sawchenko PE
J Comp Neurol; 1999 Dec; 415(3):285-312. PubMed ID: 10553117
[TBL] [Abstract][Full Text] [Related]
17. Urocortin 2 expression in the rat gastrointestinal tract under basal conditions and in chemical colitis.
Chang J; Hoy JJ; Idumalla PS; Clifton MS; Pecoraro NC; Bhargava A
Peptides; 2007 Jul; 28(7):1453-60. PubMed ID: 17586086
[TBL] [Abstract][Full Text] [Related]
18. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I.
Pedersen WA; Wan R; Zhang P; Mattson MP
J Neurosci; 2002 Jan; 22(2):404-12. PubMed ID: 11784785
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK.
Baxter GF; Mocanu MM; Brar BK; Latchman DS; Yellon DM
J Cardiovasc Pharmacol; 2001 Dec; 38(6):930-9. PubMed ID: 11707697
[TBL] [Abstract][Full Text] [Related]
20. Urocortin II is expressed in human pregnant myometrial cells and regulates myosin light chain phosphorylation: potential role of the type-2 corticotropin-releasing hormone receptor in the control of myometrial contractility.
Karteris E; Hillhouse EW; Grammatopoulos D
Endocrinology; 2004 Feb; 145(2):890-900. PubMed ID: 14592950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
